RevenueThe total money the company brought in from sales, before subtracting any costs.
$302Kβ² +78.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
79.7%β² +1.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$8Mβ² +8.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$5Mβ² +20.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
621Kβ² +102.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$655Kβ² +$80K YoY
StockOtter Β· stockotter.space
About NEXALIN TECHNOLOGY INC
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)